CervoMed CRVO
NASDAQ CRVO
$2.24 -0.10 (-4.27%)
At close: Oct 22, 2026 · 4:00 PM EDT

CervoMed (CRVO) Non Operating Interest Expenses (2010 - 2017)

Updated

CervoMed's Non Operating Interest Expenses came in at $587.00 for FY2022.

Analysis

CervoMed (CRVO) Non Operating Interest Expenses (2010 - 2017) Analysis & Trends

Going back to FY2010, CervoMed's Non Operating Interest Expenses data covers 8 years.

  • The FY2022 figure represents the highest annual Non Operating Interest Expenses in data going back to FY2010.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn -
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn 217.00 Mn
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn -
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn -
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn 462.00 Mn
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn 435.00 Mn
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn 673.00 Mn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn 247.00 Mn
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn -
10 CervoMed 23.05 Mn -62.97 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2017 18,889.00
Mar 31, 2017 55,719.00
Dec 31, 2016 28,832.00
Sep 30, 2016 1,378.00
Jun 30, 2016 6,216.00
Mar 31, 2016 21.00
Dec 31, 2015 152,802.00
Sep 30, 2015 76,170.00
Jun 30, 2015 33,337.00
Mar 31, 2015 50,810.00
Dec 31, 2014 -8,045.00
Sep 30, 2014 86,670.00
Jun 30, 2014 136,584.00
Mar 31, 2014 58,294.00
Dec 31, 2013 55,061.00
Sep 30, 2013 13,365.00
Jun 30, 2013 35,084.00
Mar 31, 2013 -22,971.00
Dec 31, 2012 272,325.00
Sep 30, 2012 172,057.00
API Access

CervoMed Non Operating Interest Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-interest-expenses&ticker=CRVO&period=max&api_key=YOUR_API_KEY